Mydecine Innovations Group Appoints Josephine Wu to Board of Directors Feb 3, 2021 07:30AM
Mydecine Innovations Group Receives Conditional Approval to List on NEO Exchange Feb 1, 2021 07:30AM
Mydecine Innovations Group Sponsors Study on Neuron Level Response to Psilocybin at University of Maryland Jan 28, 2021 07:30AM
Mydecine Innovations Group Files Application to list to the NASDAQ Jan 27, 2021 07:30AM
Mydecine Innovations Group Included in First-Ever Psychedelics ETF Jan 22, 2021 07:30AM


Jan 11, 2021 07:30AM Mydecine Innovations Group Appoints Gordon Neal to Board of Directors and Dean Ditto as Chief Financial Officer
Jan 7, 2021 07:30AM Mydecine Innovations Group Shares Intellectual Property Update
Jan 5, 2021 07:30AM Mydecine Innovations Group Sponsors First Lab-Based Study of Established Microdosers at Macquarie University in Australia
Dec 21, 2020 07:30AM Mydecine Innovations Group Engages ethica CRO as Contract Research Organization Partner for Phase 2A PTSD Clinical Trials
Dec 15, 2020 07:30AM Mydecine Innovations Group Engages the ProPharma Group to Proceed with FDA Filings and Approval for Novel Research and Multiple Phase Clinical Trials
Dec 10, 2020 07:30AM Mydecine Innovations Group Partners with Microdose Psychedelic Insights to Present a Free, Live Webinar Series on The Renaissance of Psychedelics
Dec 8, 2020 07:30AM Mydecine Innovations Group to Make First Commercial Export of Legal Psilocybin Mushrooms
Nov 24, 2020 01:23AM Mydecine Innovations Group to Restate Financial Statements
Nov 17, 2020 08:00AM Mydecine Innovations Group Offers Management and Clinical Trials Update